These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 25150873)

  • 1. Pharmacogenomics in the development and characterization of atheroprotective drugs.
    Valanti E; Tsompanidis A; Sanoudou D
    Methods Mol Biol; 2014; 1175():259-300. PubMed ID: 25150873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
    Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
    Otocka-Kmiecik A; Mikhailidis DP; Nicholls SJ; Davidson M; Rysz J; Banach M
    Prog Lipid Res; 2012 Oct; 51(4):314-24. PubMed ID: 22609245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events.
    McCullough PA; Ahmed AB; Zughaib MT; Glanz ED; Di Loreto MJ
    Rev Cardiovasc Med; 2011; 12(4):173-85. PubMed ID: 22249508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for low high-density lipoproteins.
    Hafiane A; Kellett S; Genest J
    Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in HDL-based therapies for atherosclerosis.
    Chyu KY; Peter A; Shah PK
    Curr Atheroscler Rep; 2011 Oct; 13(5):405-12. PubMed ID: 21744164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
    Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
    Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.
    Klingenberg R; Hansson GK
    Eur Heart J; 2009 Dec; 30(23):2838-44. PubMed ID: 19880848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.
    Shah PK
    Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concept of reverse cholesterol transport and novel strategy for atheroprotection.
    Ono K
    J Cardiol; 2012 Nov; 60(5):339-43. PubMed ID: 23063661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.